<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther (Heidelb)</journal-id><journal-title-group><journal-title>Dermatology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8210</issn><issn pub-type="epub">2190-9172</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39112824</article-id><article-id pub-id-type="pmc">11393223</article-id>
<article-id pub-id-type="publisher-id">1239</article-id><article-id pub-id-type="doi">10.1007/s13555-024-01239-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Highlights of Gene and Cell Therapy for Epidermolysis Bullosa and Ichthyosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koutsoukos</surname><given-names>Stefanos A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bilousova</surname><given-names>Ganna</given-names></name><address><email>ganna.bilousova@cuanschutz.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wmf1y16</institution-id><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Department of Dermatology, </institution><institution>University of Colorado Anschutz Medical Campus, </institution></institution-wrap>Aurora, CO 80045 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wmf1y16</institution-id><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Gates Institute, </institution><institution>University of Colorado Anschutz Medical Campus, </institution></institution-wrap>Aurora, CO 80045 USA </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>14</volume><issue>9</issue><fpage>2379</fpage><lpage>2392</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Advancements in the molecular genetics of epidermolysis bullosa (EB) and ichthyosis, two rare inherited skin conditions, have enabled the identification of genetic variants that cause these diseases. Alongside technological advancements in genetic medicine, the identification of variants causal of these rare skin conditions has led to preclinical research and the clinical development of various in vivo and ex vivo gene and cell therapies for their treatment. Gene and cell therapies are considered to be the most advanced forms of personalized medicine, demonstrating safety and efficacy in numerous rare diseases. Although the orphan drug development boom has resulted in regulatory approval of multiple gene and cell therapies for various rare conditions, the application of these modalities to rare inherited skin conditions remains limited. Nonetheless, there are successful examples of both in vivo gene therapy- and ex vivo cell therapy-based approaches developed to treat EB and ichthyosis. This review highlights preclinical research and the clinical development of gene and cell therapies for multiple subtypes of these two devastating congenital skin conditions, including a gene therapy recently approved by the U.S. Food and Drug Administration for the treatment of recessive dystrophic EB.</p></abstract><abstract id="Abs2" abstract-type="plain-language-summary"><title>Plain Language Summary</title><p id="Par2">Advances in genetics research for skin diseases such as epidermolysis bullosa and ichthyosis have led to the discovery of many new subtypes of these severe skin conditions. Identifying new subtypes has in turn led to new treatments for these conditions, including gene and cell therapies. Gene and cell therapies aim to address the underlying genetic causes of disease and have already shown success in the clinic. While the development of such treatments for rare skin diseases has been limited, there are notable examples of gene and cell therapies developed for epidermolysis bullosa and ichthyosis. This review highlights recent developments in gene and cell therapy for epidermolysis bullosa and ichthyosis, including a newly approved gene therapy for recessive dystrophic epidermolysis bullosa.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cell therapy</kwd><kwd>Epidermolysis bullosa</kwd><kwd>Gene therapy</kwd><kwd>Ichthyosis</kwd><kwd>Rare disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Healthcare Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="d33e181">
      <title>Key Summary Points</title>
      <p id="Par3">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Advances in the molecular genetics of epidermolysis bullosa and ichthyosis, two rare inherited skin conditions, have allowed for the preclinical and clinical development of gene and cell therapies.</td></tr><tr><td align="left">Although regulatory agency incentives have broadly increased research, development, and market expenditures for rare diseases overall, rare dermatologic disorders have been relatively neglected.</td></tr><tr><td align="left">Gene and cell therapies for epidermolysis bullosa and ichthyosis are broadly modality agnostic and based on a variety of different technologies.</td></tr><tr><td align="left">The U.S. Food and Drug Administration approved the first gene therapy, Beremagene Geperpavec, for the treatment of recessive dystrophic epidermolysis bullosa in 2023.</td></tr><tr><td align="left">Gene therapy for the most common type of ichthyosis, lamellar ichthyosis caused by biallelic pathogenic variants in <italic>TGM1</italic>, is currently being developed using an engineered herpes simplex virus type 1 vector.</td></tr></tbody></table></table-wrap>
</p>
    </sec>
    <sec id="Sec2">
      <title>Introduction</title>
      <p id="Par4">New insights into the molecular genetics of rare skin conditions such as epidermolysis bullosa (EB) and ichthyosis, along with technological advances in genetic medicine for rare monogenic diseases, have allowed for the research and development of gene and cell therapies for these devastating conditions.</p>
      <p id="Par5">Gene therapy, including both gene replacement and gene editing approaches, aims to either replace pathogenic alleles with their wildtype counterparts or permanently edit pathogenic variants in the endogenous genome. These gene therapy technologies have been evaluated in both preclinical and clinical settings, resulting in precise gene replacement or genetic correction for numerous rare inherited skin conditions. Cell therapy, which involves the use of gene therapies in combination with cell-based approaches, is another promising modality for the treatment of rare inherited skin conditions.</p>
      <p id="Par6">In this review, gene replacement and gene editing strategies delivered directly to an individual (by either viral or nonviral means) will be referred to as in vivo gene therapy, as illustrated in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. Gene replacement and gene editing methods performed on cultured patient cells (such as dermal fibroblasts, keratinocytes, and induced pluripotent stem [iPS] cells), which are then transplanted to affected individuals, will be referred to as ex vivo cell therapy, as illustrated in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>. This review will highlight these therapeutic modalities as they relate to the treatment of various subtypes of both EB and ichthyosis.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>In vivo gene therapy for epidermolysis bullosa and ichthyosis. In vivo gene therapy approaches for epidermolysis bullosa and ichthyosis, including gene replacement and gene editing, can be delivered by both viral and nonviral vectors. Beremagene Geperpavec (a gene therapy indicated for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa with mutations in the gene encoding the type VII collagen alpha-1(VII) chain [<italic>COL7A1</italic>]) and KB105 (an investigational gene therapy for lamellar ichthyosis caused by mutations in the transglutaminase 1 gene [<italic>TGM1</italic>]) both use a herpes simplex type 1 viral vector for the delivery of <italic>COL7A1</italic> and <italic>TGM1,</italic> respectively. Illustration was created with BioRender.com</p></caption><graphic xlink:href="13555_2024_1239_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Ex vivo cell therapy for the treatment of epidermolysis bullosa. Ex vivo cell therapy approaches, which have only been described for epidermolysis bullosa so far, require a primary specimen to be collected from a patient. These primary specimens are then genetically manipulated (sometimes alongside reprogramming) to either replace the pathogenic <italic>COL7A1</italic> allele or correct the endogenous pathogenic variant using the CRISPR/Cas9 gene-editing technology. Corrected primary specimens can be transplanted directly onto the patient or grafted by epidermal sheets. Genetically corrected induced pluripotent stem cells can be differentiated into fibroblasts and keratinocytes and similarly, be grafted directly onto patients. Illustration was created with BioRender.com</p></caption><graphic xlink:href="13555_2024_1239_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Methods</title>
      <p id="Par7">A modality and stage of development agnostic literature review was performed by searching PubMed to identify relevant primary research relating to the research and development of therapies for epidermolysis bullosa, ichthyosis, and their subtypes.</p>
      <p id="Par8">This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.</p>
    </sec>
    <sec id="Sec4">
      <title>Epidermolysis Bullosa and Its Subtypes</title>
      <p id="Par9">Epidermolysis bullosa is a group of rare inherited skin disorders characterized by skin fragility, blistering, and internal mucous membrane lesions. Twenty-one different genes have been implicated in EB of which most encode proteins localized to the dermal&#x2013;epidermal junction [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <sec id="Sec5">
        <title>Recessive Dystrophic Epidermolysis Bullosa</title>
        <sec id="Sec6">
          <title>Genetics and Clinical Presentation</title>
          <p id="Par10">Often characterized as the most severe subtype of EB, recessive dystrophic EB (RDEB) (OMIM #226600) is caused by loss-of-function mutations in <italic>COL7A1</italic>, a gene encoding type VII collagen (collagen VII). Collagen VII is greatly reduced or absent in the fibroblasts and keratinocytes of individuals with RDEB, leading to the malformation or absence of anchoring fibrils and dermal&#x2013;epidermal junction tissue separation. The disease causes skin fragility and predisposes affected individuals to severe blistering with minimal trauma, milia, atrophic scarring, dystrophic or absent nails, and alopecia. The mutational spectrum of RDEB spans all 118 exons of the <italic>COL7A1</italic> gene but hotspot mutations have been reported that are associated with ethnicity [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
        </sec>
        <sec id="Sec7">
          <title>Incidence and Prevalence</title>
          <p id="Par11">An analysis of the U.S. National Epidermolysis Bullosa Registry revealed the incidence and prevalence of RDEB to be 3.05 per one million live births and 1.35 per one million live births, respectively [<xref ref-type="bibr" rid="CR3">3</xref>]. However, genotypic modeling of publicly available whole-exome and whole-genome data estimates an incidence of 95 cases per one million births. Chronic wounding and fibrosis associated with RDEB are believed to promote the development of aggressive cutaneous squamous cell carcinoma (cSCC), which is the leading cause of premature death in individuals with severe and intermediate RDEB [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. RDEB affects numerous organ systems, and extracutaneous manifestations of disease include anemia, growth retardation, dental caries, pseudosyndactyly, esophageal strictures, malnutrition, and ocular involvement [<xref ref-type="bibr" rid="CR4">4</xref>]. Considering the severe manifestation of RDEB and significant reduction in quality of life of affected individuals, extensive research efforts have been undertaken to investigate novel treatments for RDEB. Highlights of these research and development efforts are described in the following text and summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Gene and cell therapies for recessive dystrophic epidermolysis bullosa in preclinical research and clinical development</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Indication</th><th align="left">Stage</th><th align="left">Modality</th><th align="left">Description</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">RDEB</td><td align="left">Approved (U.S. Food and Drug Administration)</td><td align="left">Gene therapy</td><td align="left"><italic>COL7A1</italic> transgene delivered by an engineered HSV-1 vector</td><td align="left">[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td align="left">RDEB</td><td align="left">Phase 3</td><td align="left">Cell therapy</td><td align="left">Genetically corrected autologous epidermal skin grafts</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr><td align="left">RDEB</td><td align="left">Preclinical</td><td align="left">Cell therapy</td><td align="left">CRISPR/Cas9 correction of <italic>COL7A1</italic> in primary keratinocytes</td><td align="left">[<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td align="left">RDEB</td><td align="left">Preclinical</td><td align="left">Cell therapy</td><td align="left">CRISPR/Cas9-based correction of <italic>COL7A1</italic> in iPSCs and generation of organotypic induced skin composites</td><td align="left">[<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">RDEB</td><td align="left">Preclinical</td><td align="left">Cell therapy</td><td align="left">CRISPR/Cas9-based correction of iPSCs and generation of human skin equivalents</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>COL7A1</italic> Gene encoding the type VII collagen alpha-1(VII) chain,<italic> CRISPR/Cas9</italic> gene-editing technology, <italic>HSV-1</italic> herpes simplex virus type 1, <italic>iPSCs</italic> induced pluripotent stem cells, <italic> RDEB</italic> recessive dystrophic epidermolysis bullosa</p></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="Sec8">
          <title>Preclinical and Clinical Studies</title>
          <sec id="Sec9">
            <title>Genetically Corrected Autologous Epidermal Grafts</title>
            <p id="Par12">In 2016, Siprashvili et al. conducted a phase 1 clinical trial investigating the use of genetically corrected autologous epidermal grafts to treat RDEB [<xref ref-type="bibr" rid="CR6">6</xref>]. Autologous keratinocytes from four patients with RDEB were transduced with a retrovirus encoding human <italic>COL7A1</italic> and assembled into epidermal sheets, which were grafted onto six wounds per patient. All 24 grafts were well tolerated without serious adverse events. Collagen VII expression was observed in nine out of ten biopsies 3 months post-engraftment. Further, RDEB wounds treated with grafts displayed 87% healing at 3 months, 67% healing at 6 months, and 50% healing at 12&#xA0;months compared to baseline wound sites [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
            <p id="Par13">A subsequent phase 1/2a clinical trial reported by Eichstadt et al. used the same methods on seven adults between 2013 and 2017, with follow-up for 2 to 5 years [<xref ref-type="bibr" rid="CR7">7</xref>]. No serious adverse events occurred. At 6 months, wound healing of &#x2265; 50% was present in 95% of treated wounds and in 0% of untreated control wounds. After 1 year, 68% of treated wounds had &#x2265; 50% healing, compared to 17% of control wounds. After 2 years, 71% of treated wounds had &#x2265; 50% healing compared with 17% of control wounds.</p>
            <p id="Par14">Although this approach showed promise for wound healing in RDEB, the response was variable among patients, and grafted sites generally declined after 12&#xA0;months in the single-center phase 1 clinical trial. In the study of Eichstadt et al. [<xref ref-type="bibr" rid="CR7">7</xref>], collagen VII expression was reported to persist for up to 2 years in two participants. However, the use of retrovirus to generate collagen VII-corrected grafts could have safety limitations, as this approach can lead to undesired integrations of the viral genome throughout recipient cells. While this research provides a strong basis for developing cell-based approaches to treat RDEB, advanced methods of genetic correction would offer safer treatments and reduce unintended consequences of viral genome integration.</p>
          </sec>
          <sec id="Sec10">
            <title>CRISPR/Cas9 Editing in Primary Patient-Derived Keratinocytes</title>
            <p id="Par15">In 2017, Hainzl et al. described a <italic>COL7A1</italic> CRISPR/Cas9-based gene editing strategy in primary patient-derived keratinocytes [<xref ref-type="bibr" rid="CR8">8</xref>]. CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) was used to correct a common insertion variant in exon 80 of <italic>COL7A1</italic> (c.6527insC). Corrected keratinocyte clones were able to express and secrete collagen VII at levels similar to control keratinocytes. Transplantation of skin equivalents derived from the corrected keratinocytes onto an immunodeficient mouse rescued the disease phenotype with normal collagen VII localization at the basement membrane zone. In this study, the authors demonstrated the potential of CRISPR/Cas9 technology as a possible ex vivo treatment approach for genetic skin diseases.</p>
          </sec>
          <sec id="Sec11">
            <title>CRISPR/Cas9 Editing in iPSCs and Generation of Human Skin Equivalents</title>
            <p id="Par16">In 2019, Jackow et al. reported a CRISPR/Cas9-based editing approach of <italic>COL7A1</italic> for the correction of RDEB causing variants in iPS cells [<xref ref-type="bibr" rid="CR9">9</xref>]. The authors demonstrated the successful correction of two pathogenic variants in exon 19 and exon 32 of the <italic>COL7A1</italic> gene by homology-directed repair in iPS cells derived from patients with RDEB. Human skin equivalents were generated from genetically corrected iPS cells and grafted onto immunodeficient mice. Grafts showed normal expression of collagen VII at the basement membrane zone and the restoration of anchoring fibrils two months post grafting. Safety assessment of Cas9 cleavage activity did not reveal any unintended nuclease activity.</p>
          </sec>
          <sec id="Sec12">
            <title>Transgenic <italic>COL7A1</italic> Delivery by an Engineered human Herpes Simplex Virus Type 1 Vector</title>
            <p id="Par17">In 2022, an engineered, non-integrating, replication-incompetent human herpes simplex virus type 1 (HSV-1) vector formulated in a gel was reported to be both safe and effective in the healing of wounds in individuals living with RDEB. In a randomized, placebo-controlled, phase 1 and 2 clinical trial (ClinicalTrials.gov identifier: NCT03536143), sponsored by Krystal Biotech, Inc. (Pittsburgh, PA, USA), the safety and efficacy of this therapeutic, known as Beremagene Geperpavec (B-VEC), was evaluated in nine individuals with RDEB across 28 wounds [<xref ref-type="bibr" rid="CR10">10</xref>]. The primary outcome measures of the study were met. Notably, ten out of 12 wounds (83%) closed in individuals receiving B-VEC compared to one out of seven (14%) in individuals receiving placebo after 12&#xA0;weeks, a difference of 69%. The median time to complete closure was 13.5&#xA0;days in individuals treated with B-VEC and 22.5&#xA0;days in those receiving placebo. The median duration of closure was 103.0&#xA0;days in the B-VEC-treated group and 16.5&#xA0;days in the placebo group. This phase 1 and 2 study showed that B-VEC is a safe and effective therapy in the promotion of wound healing in individuals living with RDEB.</p>
            <p id="Par18">B-VEC was further evaluated in a phase 3, double-blind, intrapatient randomized, placebo-controlled trial that included affected individuals aged &#x2265; 6 months [<xref ref-type="bibr" rid="CR11">11</xref>]. A primary wound pair was selected for each patient and matched according to size, region, and appearance. Each wound was assigned to either the group receiving weekly application of B-VEC or the group receiving placebo. Complete wound healing was observed in 67% of wounds treated with B-VEC compared to 22% of wounds exposed to placebo across 31 patients. Complete wound healing at 3 months was observed in 71% of wounds treated with B-VEC compared to 20% of wounds exposed to placebo. Adverse events experienced by individuals receiving B-VEC included pruritus and chills. In May of 2023, B-VEC was approved by the U.S. Food and Drug Administration. This was the first topical gene therapy approved for the treatment of wounds in patients with RDEB.</p>
          </sec>
          <sec id="Sec13">
            <title>GMP Compatible CRISPR/Cas9-Based Editing of iPSCs and Generation of Induced Skin Composites</title>
            <p id="Par19">In 2024, Neumayer et al. reported a scalable, Good Manufacturing Practice (GMP) compatible, autologous cell therapy for RDEB [<xref ref-type="bibr" rid="CR12">12</xref>] that was able to generate clinical-grade iPS cell-derived organotypic induced skin composite (iSC) grafts for the treatment of wounds in patients with collagen VII deficiency. The approach involved a combined reprogramming and CRISPR-based genetic correction to generate <italic>COL7A1</italic>-corrected clonal iPS cells from primary patient fibroblasts and, further, iSC grafts using a novel two-dimensional organoid differentiation protocol. The authors reported that iPS cell-derived iSC generation was reproducible using cells from four patients&#xA0;with RDEB with different pathogenic variants, and the grafts were able to develop into stable stratified skin with functional collagen VII restoration in immune-compromised mice.</p>
            <p id="Par20">Both the Jackow et al. [<xref ref-type="bibr" rid="CR9">9</xref>] and Neumayer et al. [<xref ref-type="bibr" rid="CR12">12</xref>] studies report, for the first time, the generation of an iPS cell- and CRISPR/Cas9-based cell therapy for the treatment of RDEB. Although still early in the preclinical stages, these methods represent safer and potentially more durable alternatives compared to previous studies using viral approaches for transgenic <italic>COL7A1</italic> delivery.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Sec14">
        <title>Epidermolysis Bullosa Simplex</title>
        <sec id="Sec15">
          <title>Genetics and Clinical Presentation</title>
          <p id="Par21">Epidermolysis bullosa simplex (EBS) (OMIM #131760) is a rare inherited skin blistering condition caused by monoallelic pathogenic variants in <italic>KRT5</italic> and <italic>KRT14</italic>, genes which encode keratin 5 and keratin 14, respectively, that are localized to the epidermal basal layer [<xref ref-type="bibr" rid="CR13">13</xref>]. Pathogenic variants in both <italic>KRT5</italic> and <italic>KRT14</italic> have been shown to disrupt the central alpha helical segment of these molecules and further compromise the structure and function of the cell cytoskeleton and its ability to accommodate mechanical stress [<xref ref-type="bibr" rid="CR14">14</xref>]. Structural deficits in the cytoskeleton caused by <italic>KRT5</italic> and <italic>KRT14</italic> pathogenic variants predispose the basal cell layer to fracture. Ultrastructural assessment of keratin 5 and keratin 14 abnormalities reveals cell vacuolization, keratin filament aggregation, and blister formation [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
          <p id="Par22">Clinically, all forms of EBS manifest with skin blistering that is usually induced by mechanical friction or trauma exposure. Additional manifestations include palmoplantar keratoderma (thickening of the palmar and plantar skin), nail dystrophy and shedding, alopecia, and mucosal tissue involvement (rare observation usually exclusive to more severe cases). Erosions and blistering heal without scarring but result in hyperpigmentation.</p>
          <p id="Par23">The age of onset in EBS is variable, but most severe cases present at birth and less severe cases during the second or third decade of life [<xref ref-type="bibr" rid="CR16">16</xref>]. Improvement with age is common.</p>
          <p id="Par24">EBS is typically inherited in an autosomal dominant manner, but 30% of cases in the Middle East are caused by recessive variants [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Most pathogenic variants causal in EBS induce a dominant negative effect by which mutant molecules interfere with the wildtype molecules. This interaction has major implications for the development of therapies for EBS.</p>
        </sec>
        <sec id="Sec16">
          <title>Preclinical and Clinical Studies</title>
          <p id="Par25">In 2017, Kocher et al. reported an efficient homology-directed repair of dominant negative <italic>KRT14</italic> variants with CRISPR/Cas9 nickase [<xref ref-type="bibr" rid="CR19">19</xref>]. A hotspot mutation in exon six of the <italic>KRT14</italic> gene, which causes generalized severe EBS, was corrected using a double-nicking strategy targeted against exon 7 and followed by homology-directed repair. The use of Cas9 nickase (D10A), a single guide RNA, and minicircle donor vector with the donor template resulted in a recombination efficiency of &gt; 30% and correction of the negative <italic>KRT14</italic> allele. Immunofluorescence analysis showed phenotypic correction by the absence of keratin 14 aggregates within the cytoplasm. The safety profile of this double nicking strategy was found to be promising, with no detectable off-target activity in a set of predicted off-target genes confirmed by next-generation sequencing.</p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>Junctional Epidermolysis Bullosa</title>
        <sec id="Sec18">
          <title>Genetics and Clinical Presentation</title>
          <p id="Par26">Junctional epidermolysis bullosa (JEB) (OMIM #226650) is a rare inherited skin blistering disorder caused by biallelic pathogenic variants in the <italic>LAMA3</italic>, <italic>LAMB3</italic>, and <italic>LAMC2</italic> genes and is characterized by skin and mucous membranes. LAMA3, LAMB3, and LAMC2 proteins, together, assemble into the laminin 332 heterotrimer, also referred to as LAM5 [<xref ref-type="bibr" rid="CR20">20</xref>]. Pathogenic variants in the LAM5 subunits affect the ability of these polypeptides to assemble into a trimeric molecule, compromising their secondary structure and, further, their ability to form intracellular anchoring fibrils in the lamina densa.</p>
          <p id="Par27">JEB is classified into two subtypes: generalized and localized. JEB generalized severe is the result of little or no functional protein [<xref ref-type="bibr" rid="CR21">21</xref>]. Disease severity is associated with premature termination of the protein [<xref ref-type="bibr" rid="CR22">22</xref>]. JEB generalized intermediate results from single amino acid substitutions and splice-junction variants. JEB presents with blistering, which can be severe but typically heals with minimal scarring [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
          <p id="Par28">Pathogenic variants in <italic>COL17A1</italic>, the gene encoding type XVII collagen (collagen XVII), have also been determined to be causal in JEB, specifically the generalized intermediate subtype [<xref ref-type="bibr" rid="CR25">25</xref>]. Collagen XVII is a key component of hemidesmosomes, which anchor basal keratinocytes to the underlying basement membrane. Collagen XVII deficiency causes skin fragility, dental manifestations, and alopecia, all of which are characteristic symptoms of JEB generalized intermediate.</p>
        </sec>
        <sec id="Sec19">
          <title>Preclinical and Clinical Studies</title>
          <p id="Par29">In 2006, the first ex vivo gene replacement and cell transplantation approach for JEB was reported [<xref ref-type="bibr" rid="CR26">26</xref>]. Epidermal stem cells were isolated from an adult with LAM5-&#x3B2;3-deficient JEB and transduced with a retroviral vector expressing <italic>LAMB3</italic> complementary DNA (cDNA). Genetically corrected keratinocytes were used to generate epidermal grafts. Upon transplantation back to the patient, the grafts showed restored LAM5-&#x3B2;3 expression and proper assembly of functional LAM5, resulting in a durable, adherent epidermis throughout the 1-year follow-up period. This study demonstrated a successful ex vivo gene replacement and transplantation strategy that resulted in a fully functional epidermis and amelioration of the disease.</p>
          <p id="Par30">In 2017, Bauer et al. published another gene replacement and transplantation approach [<xref ref-type="bibr" rid="CR27">27</xref>]. A 49-year-old woman with generalized intermediate, laminin-322-B3-deficient JEB presented with a large 80-cm<sup>2</sup> wound on her leg. Primary keratinocytes were transduced with a retroviral vector expressing full-length <italic>LAMB3</italic> cDNA, as used in the previously described study. Epidermal sheets generated with corrected keratinocytes were grafted onto the leg ulceration, resulting in wound closure with no blister formation throughout the 16-month follow-up period.</p>
          <p id="Par31">In the same year, a similar approach regenerated the entire human epidermis in a 7-year-old with JEB [<xref ref-type="bibr" rid="CR28">28</xref>]. About 80% of the individual&#x2019;s total body surface area was replaced with transgenic epidermal grafts generated from genetically corrected autologous keratinocytes. Clonal tracing revealed that a limited number of long-lived stem cells could sustain the fully regenerated human epidermis, confirming the feasibility of ex vivo gene and cell therapy approaches to replace defective skin with corrected skin.</p>
          <p id="Par32">In 2018, Benati et al. used CRISPR/Cas9 was used to correct <italic>LAMB3</italic> variants in keratinocytes derived from an individual with JEB [<xref ref-type="bibr" rid="CR29">29</xref>]. CRISPR/Cas9 was used to restore LAMB3 expression in vitro, followed by transplantation onto immunodeficient mice. The grafting of genetically corrected skin equivalents onto immunodeficient mice demonstrated a complete rescue of dermal&#x2013;epidermal junction integrity.</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec20">
      <title>Ichthyosis and Its Subtypes</title>
      <p id="Par33">Inherited ichthyotic conditions are genetic disorders commonly characterized by general dry skin, scaling, hyperkeratosis, and erythroderma [<xref ref-type="bibr" rid="CR30">30</xref>]. Recent advances in human genetics and next-generation sequencing have enabled the identification of numerous genes causal in their pathogenesis [<xref ref-type="bibr" rid="CR31">31</xref>]. Ichthyotic conditions are classified as either syndromic or non-syndromic [<xref ref-type="bibr" rid="CR32">32</xref>]. Non-syndromic ichthyosis presents exclusively in the skin, while syndromic subtypes involve multiple body systems.</p>
      <p id="Par34">Due to their rare and ultrarare incidence, gene therapy for the ichthyoses is rarely investigated. However, gene therapy for ichthyosis is a promising therapeutic approach due to the monogenic nature and tissue accessibility associated with this condition. Here we review in vivo gene therapies for nonsyndromic ichthyosis (specifically autosomal recessive congenital ichthyosis) in both the preclinical and clinical settings.</p>
      <sec id="Sec21">
        <title>Autosomal Recessive Congenital Ichthyosis</title>
        <p id="Par35">Autosomal recessive congenital ichthyosis (ARCI) is a genetically and phenotypically heterogenous group of disorders that includes harlequin ichthyosis (HI), lamellar ichthyosis (LI), and congenital ichthyosiform erythroderma [<xref ref-type="bibr" rid="CR33">33</xref>]. ARCI is caused by pathogenic variants in multiple genes, including <italic>TGM1</italic> [<xref ref-type="bibr" rid="CR34">34</xref>], <italic>ABCA12</italic> [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], <italic>CYP4F22</italic> [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], <italic>ALOXE3/ALOX12B</italic> [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], <italic>NIPAL4</italic> [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], <italic>CERS3</italic> [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], <italic>SDR9C7</italic> [<xref ref-type="bibr" rid="CR45">45</xref>&#x2013;<xref ref-type="bibr" rid="CR48">48</xref>], <italic>PNPLA1</italic> [<xref ref-type="bibr" rid="CR49">49</xref>&#x2013;<xref ref-type="bibr" rid="CR56">56</xref>], <italic>SLC27A4</italic> [<xref ref-type="bibr" rid="CR57">57</xref>&#x2013;<xref ref-type="bibr" rid="CR66">66</xref>], and <italic>LIPN</italic> [<xref ref-type="bibr" rid="CR67">67</xref>]. Overall, ARCI has an incidence of about 1 per 100,000 general population, and 24&#x2013;34% of cases are caused by pathogenic variants exclusively in <italic>TGM1</italic> [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p>
        <sec id="Sec22">
          <title>Lamellar Ichthyosis</title>
          <sec id="Sec23">
            <title>Genetics and Clinical Presentation</title>
            <p id="Par36">About 70&#x2013;90% of cases of LI (OMIM #242300) have pathogenic variants in the gene encoding transglutaminase 1 (<italic>TGM1</italic>). LI typically presents at birth with a collodion membrane, which is replaced by large, brown, plate-like scales in a generalized distribution. Erythroderma may be present but is usually mild. Scaling leads to sweat duct obstruction and severe heat intolerance. As LI is one of the most common subtypes of ichthyosis, a multitude of gene and cell therapies for its treatment have been investigated in both preclinical and clinical settings.</p>
          </sec>
          <sec id="Sec24">
            <title>Preclinical and Clinical Studies</title>
            <p id="Par37">In 1996, Choate et al. described one of the first experimental gene therapies for LI caused by transglutaminase 1 (TGM1) deficiency [<xref ref-type="bibr" rid="CR69">69</xref>]. The authors showed that TGM1 expression could be restored in primary patient keratinocytes using a retroviral vector. These retrovirally-corrected keratinocytes also demonstrated restored involucrin cross-linking and normal in vitro measures of cornification.</p>
            <p id="Par38">In 2021, Freedman et al. described a modified herpes simplex virus type 1 vector (KB105) encoding human TGM1 for the treatment of ARCI [<xref ref-type="bibr" rid="CR70">70</xref>]. KB105 efficiently transduced TGM1-deficient human keratinocytes, promoted TGM1 expression, and rescued enzymatic deficiency. In vivo topical application restored protein expression in the epidermal layer without inducing fibrosis, necrosis, or acute inflammation. KB105 is currently being investigated in a phase &#xBD; clinical trial (ClinicalTrials.gov identifier: NCT04047732).</p>
            <p id="Par39">In 2021, Dang et al. reported the correction of pathogenic variants in TGM1 by adenine base editing in human embryos [<xref ref-type="bibr" rid="CR71">71</xref>]. Two different adenine base editors in combination with truncated single guide RNAs (sgRNAs) were used to repair the pathogenic variant in mutant zygotes, providing feasibility data for developing in utero gene correction approaches for ichthyosis.</p>
          </sec>
        </sec>
        <sec id="Sec25">
          <title>Harlequin Ichthyosis</title>
          <sec id="Sec26">
            <title>Genetics and Clinical Presentation</title>
            <p id="Par40">Harlequin ichthyosis (OMIM #242500) is widely considered to be the most severe subtype of ichthyosis. The clinical presentation of HI includes thick, plate-like scales with severe ectropion, eclabium, and flattening of the ears [<xref ref-type="bibr" rid="CR72">72</xref>]. The development of the skin in utero is characterized by hyperkeratosis of the hair canals and ultrastructural abnormalities, including abnormal lamellar granules in the fetal epidermis [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. In 2005, two sets of authors (Akiyama et al. [<xref ref-type="bibr" rid="CR36">36</xref>] and Kelsell et al. [<xref ref-type="bibr" rid="CR35">35</xref>]) reported that HI is caused by loss-of-function mutations in the gene <italic>ABCA12</italic>, which encodes the adenosine triphosphate (ATP)-binding cassette family subfamily A member 12. Loss-of-of-function variants in <italic>ABCA12</italic> disrupt normal lipid transport in lamellar granules, particularly in keratinocytes undergoing keratinization in the epidermis [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
            <p id="Par41">Translational efforts in the development of gene therapy for HI have been extensive due to its devastating clinical presentation. In 2005, Akiyama et al., in addition to characterizing its genetic etiology, also showed the rescue of lamellar granules lipid secretion through corrective gene transfer of <italic>ABCA12</italic> by transfection of a plasmid containing full-length cDNA [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
          </sec>
        </sec>
      </sec>
    </sec>
    <sec id="Sec27">
      <title>Conclusion</title>
      <p id="Par42">Overall, the research and development of gene and cell therapies for the treatment of EB and ichthyosis are in their infancy and are primarily focused on more prevalent subtypes. Recent advancements in the clinical development of products indicated for the treatment of these conditions provide a promising foundation for future research and development. However, the low incidence and prevalence of these indications continue to pose challenges in securing funding in both academic and industrial settings. In order to improve the outcomes of individuals living with rare inherited skin conditions, innovative approaches in platform technology development, alongside regulatory acceptance of these platforms, will be required to ensure that these rare and ultrarare indications are not overlooked.</p>
    </sec>
  </body>
  <back>
    <notes notes-type="author-contribution">
      <title>Author Contributions</title>
      <p>All authors contributed to the study conception and design. The literature search was performed by Stefanos A. Koutsoukos and Ganna Bilousova. The first draft of the manuscript was written by Stefanos A. Koutsoukos, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>We are grateful for funding support from the National Institutes of Health (T32AR007411), Dystrophic Epidermolysis Bullosa Research Association (DEBRA) Austria, Gates Grubstake Fund, and the Gates Frontiers Fund. No funding or sponsorship was received for the publication of this article.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Conflict of Interest</title>
        <p id="Par43">Stefanos A. Koutsoukos and Ganna Bilousova declare that they have no competing interest.</p>
      </notes>
      <notes id="FPar2">
        <title>Ethical Approval</title>
        <p id="Par44">This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Has</surname><given-names>C</given-names></name><name><surname>South</surname><given-names>A</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name></person-group><article-title>Molecular therapeutics in development for epidermolysis bullosa: update 2020</article-title><source>Mol Diagn Ther</source><year>2020</year><volume>24</volume><issue>3</issue><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s40291-020-00466-7</pub-id><pub-id pub-id-type="pmid">32328988</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Has C, South A, Uitto J. Molecular therapeutics in development for epidermolysis bullosa: update 2020. Mol Diagn Ther. 2020;24(3):299&#x2013;309. 10.1007/s40291-020-00466-7.<pub-id pub-id-type="pmid">32328988</pub-id>
<pub-id pub-id-type="doi">10.1007/s40291-020-00466-7</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>T</given-names></name><name><surname>Masunaga</surname><given-names>T</given-names></name><name><surname>Ishiko</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name></person-group><article-title>Differences in recurrent COL7A1 mutations in dystrophic epidermolysis bullosa: ethnic-specific and worldwide recurrent mutations</article-title><source>Arch Dermatol Res</source><year>2004</year><volume>295</volume><issue>10</issue><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1007/s00403-003-0444-1</pub-id><pub-id pub-id-type="pmid">14727126</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Murata T, Masunaga T, Ishiko A, Shimizu H, Nishikawa T. Differences in recurrent COL7A1 mutations in dystrophic epidermolysis bullosa: ethnic-specific and worldwide recurrent mutations. Arch Dermatol Res. 2004;295(10):442&#x2013;7. 10.1007/s00403-003-0444-1.<pub-id pub-id-type="pmid">14727126</pub-id>
<pub-id pub-id-type="doi">10.1007/s00403-003-0444-1</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JD</given-names></name></person-group><article-title>Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry</article-title><source>JAMA Dermatol</source><year>2016</year><volume>152</volume><issue>11</issue><fpage>1231</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2016.2473</pub-id><pub-id pub-id-type="pmid">27463098</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. JAMA Dermatol. 2016;152(11):1231&#x2013;8. 10.1001/jamadermatol.2016.2473.<pub-id pub-id-type="pmid">27463098</pub-id>
<pub-id pub-id-type="doi">10.1001/jamadermatol.2016.2473</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JD</given-names></name><name><surname>Bruckner-Tuderman</surname><given-names>L</given-names></name><name><surname>Eady</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification</article-title><source>J Am Acad Dermatol</source><year>2014</year><volume>70</volume><issue>6</issue><fpage>1103</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2014.01.903</pub-id><pub-id pub-id-type="pmid">24690439</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103&#x2013;26. 10.1016/j.jaad.2014.01.903.<pub-id pub-id-type="pmid">24690439</pub-id>
<pub-id pub-id-type="doi">10.1016/j.jaad.2014.01.903</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Intong-Wheeler</surname><given-names>LRA</given-names></name><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Marucci</surname><given-names>D</given-names></name><name><surname>Murrell</surname><given-names>DF</given-names></name></person-group><article-title>Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand</article-title><source>Acta Derm Venereol</source><year>2018</year><volume>98</volume><issue>1</issue><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2340/00015555-2781</pub-id><pub-id pub-id-type="pmid">28853495</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta Derm Venereol. 2018;98(1):70&#x2013;6. 10.2340/00015555-2781.<pub-id pub-id-type="pmid">28853495</pub-id>
<pub-id pub-id-type="doi">10.2340/00015555-2781</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Siprashvili</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Gorell</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa</article-title><source>JAMA</source><year>2016</year><volume>316</volume><issue>17</issue><fpage>1808</fpage><lpage>1817</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.15588</pub-id><pub-id pub-id-type="pmid">27802546</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808&#x2013;17. 10.1001/jama.2016.15588.<pub-id pub-id-type="pmid">27802546</pub-id>
<pub-id pub-id-type="doi">10.1001/jama.2016.15588</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Eichstadt</surname><given-names>S</given-names></name><name><surname>Barriga</surname><given-names>M</given-names></name><name><surname>Ponakala</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa</article-title><source>JCI Insight</source><year>2019</year><pub-id pub-id-type="doi">10.1172/jci.insight.130554</pub-id><pub-id pub-id-type="pmid">31578311</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Eichstadt S, Barriga M, Ponakala A, et al. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight. 2019. 10.1172/jci.insight.130554.<pub-id pub-id-type="pmid">31578311</pub-id>
<pub-id pub-id-type="doi">10.1172/jci.insight.130554</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Hainzl</surname><given-names>S</given-names></name><name><surname>Peking</surname><given-names>P</given-names></name><name><surname>Kocher</surname><given-names>T</given-names></name><etal/></person-group><article-title>COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><issue>11</issue><fpage>2573</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.07.005</pub-id><pub-id pub-id-type="pmid">28800953</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Hainzl S, Peking P, Kocher T, et al. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther. 2017;25(11):2573&#x2013;84. 10.1016/j.ymthe.2017.07.005.<pub-id pub-id-type="pmid">28800953</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.07.005</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jackow</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Hansen</surname><given-names>C</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><issue>52</issue><fpage>26846</fpage><lpage>26852</lpage><pub-id pub-id-type="doi">10.1073/pnas.1907081116</pub-id><pub-id pub-id-type="pmid">31818947</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Jackow J, Guo Z, Hansen C, et al. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc Natl Acad Sci USA. 2019;116(52):26846&#x2013;52. 10.1073/pnas.1907081116.<pub-id pub-id-type="pmid">31818947</pub-id>
<pub-id pub-id-type="doi">10.1073/pnas.1907081116</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevich</surname><given-names>I</given-names></name><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group><article-title>In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>4</issue><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01737-y</pub-id><pub-id pub-id-type="pmid">35347281</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780&#x2013;8. 10.1038/s41591-022-01737-y.<pub-id pub-id-type="pmid">35347281</pub-id>
<pub-id pub-id-type="doi">10.1038/s41591-022-01737-y</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Guide</surname><given-names>SV</given-names></name><name><surname>Gonzalez</surname><given-names>ME</given-names></name><name><surname>Bagci</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Trial of Beremagene Geperpavec (B-VEC) for dystrophic epidermolysis bullosa</article-title><source>N Engl J Med</source><year>2022</year><volume>387</volume><issue>24</issue><fpage>2211</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2206663</pub-id><pub-id pub-id-type="pmid">36516090</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Guide SV, Gonzalez ME, Bagci IS, et al. Trial of Beremagene Geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211&#x2013;9. 10.1056/NEJMoa2206663.<pub-id pub-id-type="pmid">36516090</pub-id>
<pub-id pub-id-type="doi">10.1056/NEJMoa2206663</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumayer</surname><given-names>G</given-names></name><name><surname>Torkelson</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>A scalable, GMP-compatible, autologous organotypic cell therapy for dystrophic epidermolysis bullosa</article-title><source>Nat Commun.</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>5834</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49400-z</pub-id><pub-id pub-id-type="pmid">38992003</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Neumayer G, Torkelson JL, Li S, et al. A scalable, GMP-compatible, autologous organotypic cell therapy for dystrophic epidermolysis bullosa. Nat Commun. 2024;15(1):5834.&#xA0;10.1038/s41467-024-49400-z<pub-id pub-id-type="pmid">38992003</pub-id>
<pub-id pub-id-type="doi">10.1038/s41467-024-49400-z</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Sprecher</surname><given-names>E</given-names></name></person-group><article-title>Epidermolysis bullosa simplex</article-title><source>Dermatol Clin</source><year>2010</year><volume>28</volume><issue>1</issue><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.det.2009.10.003</pub-id><pub-id pub-id-type="pmid">19945613</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Sprecher E. Epidermolysis bullosa simplex. Dermatol Clin. 2010;28(1):23&#x2013;32. 10.1016/j.det.2009.10.003.<pub-id pub-id-type="pmid">19945613</pub-id>
<pub-id pub-id-type="doi">10.1016/j.det.2009.10.003</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>EB</given-names></name><name><surname>McLean</surname><given-names>WH</given-names></name></person-group><article-title>Keratins and skin disorders</article-title><source>J Pathol</source><year>2004</year><volume>204</volume><issue>4</issue><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1002/path.1643</pub-id><pub-id pub-id-type="pmid">15495218</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Lane EB, McLean WH. Keratins and skin disorders. J Pathol. 2004;204(4):355&#x2013;66. 10.1002/path.1643.<pub-id pub-id-type="pmid">15495218</pub-id>
<pub-id pub-id-type="doi">10.1002/path.1643</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Uitto</surname><given-names>J</given-names></name><name><surname>Richard</surname><given-names>G</given-names></name><name><surname>McGrath</surname><given-names>JA</given-names></name></person-group><article-title>Diseases of epidermal keratins and their linker proteins</article-title><source>Exp Cell Res</source><year>2007</year><volume>313</volume><issue>10</issue><fpage>1995</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2007.03.029</pub-id><pub-id pub-id-type="pmid">17531221</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Uitto J, Richard G, McGrath JA. Diseases of epidermal keratins and their linker proteins. Exp Cell Res. 2007;313(10):1995&#x2013;2009. 10.1016/j.yexcr.2007.03.029.<pub-id pub-id-type="pmid">17531221</pub-id>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2007.03.029</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>HM</given-names></name><name><surname>Tidman</surname><given-names>MJ</given-names></name></person-group><article-title>The clinical spectrum of dystrophic epidermolysis bullosa</article-title><source>Br J Dermatol</source><year>2002</year><volume>146</volume><issue>2</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04607.x</pub-id><pub-id pub-id-type="pmid">11903238</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. Br J Dermatol. 2002;146(2):267&#x2013;74. 10.1046/j.1365-2133.2002.04607.x.<pub-id pub-id-type="pmid">11903238</pub-id>
<pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.04607.x</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Abu Sa'd</surname><given-names>J</given-names></name><name><surname>Indelman</surname><given-names>M</given-names></name><name><surname>Pfendner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population</article-title><source>J Invest Dermatol</source><year>2006</year><volume>126</volume><issue>4</issue><fpage>777</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700163</pub-id><pub-id pub-id-type="pmid">16439963</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Abu Sa&#x2019;d J, Indelman M, Pfendner E, et al. Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population. J Invest Dermatol. 2006;126(4):777&#x2013;81. 10.1038/sj.jid.5700163.<pub-id pub-id-type="pmid">16439963</pub-id>
<pub-id pub-id-type="doi">10.1038/sj.jid.5700163</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciubotaru</surname><given-names>D</given-names></name><name><surname>Bergman</surname><given-names>R</given-names></name><name><surname>Baty</surname><given-names>D</given-names></name><etal/></person-group><article-title>Epidermolysis bullosa simplex in Israel: clinical and genetic features</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><issue>4</issue><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1001/archderm.139.4.498</pub-id><pub-id pub-id-type="pmid">12707098</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Ciubotaru D, Bergman R, Baty D, et al. Epidermolysis bullosa simplex in Israel: clinical and genetic features. Arch Dermatol. 2003;139(4):498&#x2013;505. 10.1001/archderm.139.4.498.<pub-id pub-id-type="pmid">12707098</pub-id>
<pub-id pub-id-type="doi">10.1001/archderm.139.4.498</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Kocher</surname><given-names>T</given-names></name><name><surname>Peking</surname><given-names>P</given-names></name><name><surname>Klausegger</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><issue>11</issue><fpage>2585</fpage><lpage>2598</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.08.015</pub-id><pub-id pub-id-type="pmid">28888469</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Kocher T, Peking P, Klausegger A, et al. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases. Mol Ther. 2017;25(11):2585&#x2013;98. 10.1016/j.ymthe.2017.08.015.<pub-id pub-id-type="pmid">28888469</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.08.015</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Aumailley</surname><given-names>M</given-names></name><name><surname>Bruckner-Tuderman</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>WG</given-names></name><etal/></person-group><article-title>A simplified laminin nomenclature</article-title><source>Matrix Biol</source><year>2005</year><volume>24</volume><issue>5</issue><fpage>326</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2005.05.006</pub-id><pub-id pub-id-type="pmid">15979864</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Aumailley M, Bruckner-Tuderman L, Carter WG, et al. A simplified laminin nomenclature. Matrix Biol. 2005;24(5):326&#x2013;32. 10.1016/j.matbio.2005.05.006.<pub-id pub-id-type="pmid">15979864</pub-id>
<pub-id pub-id-type="doi">10.1016/j.matbio.2005.05.006</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Varki</surname><given-names>R</given-names></name><name><surname>Sadowski</surname><given-names>S</given-names></name><name><surname>Pfendner</surname><given-names>E</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name></person-group><article-title>Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><issue>8</issue><fpage>641</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1136/jmg.2005.039685</pub-id><pub-id pub-id-type="pmid">16473856</pub-id>
</element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet. 2006;43(8):641&#x2013;52. 10.1136/jmg.2005.039685.<pub-id pub-id-type="pmid">16473856</pub-id>
<pub-id pub-id-type="doi">10.1136/jmg.2005.039685</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Kiritsi</surname><given-names>D</given-names></name><name><surname>Has</surname><given-names>C</given-names></name><name><surname>Bruckner-Tuderman</surname><given-names>L</given-names></name></person-group><article-title>Laminin 332 in junctional epidermolysis bullosa</article-title><source>Cell Adh Migr</source><year>2013</year><volume>7</volume><issue>1</issue><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.4161/cam.22418</pub-id><pub-id pub-id-type="pmid">23076207</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Kiritsi D, Has C, Bruckner-Tuderman L. Laminin 332 in junctional epidermolysis bullosa. Cell Adh Migr. 2013;7(1):135&#x2013;41. 10.4161/cam.22418.<pub-id pub-id-type="pmid">23076207</pub-id>
<pub-id pub-id-type="doi">10.4161/cam.22418</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pfendner</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Lucky</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Junctional epidermolysis bullosa</article-title>
            <source>GeneReviews</source>
            <year>1993</year>
            <publisher-loc>Seattle</publisher-loc>
            <publisher-name>University of Washington</publisher-name>
          </element-citation>
          <mixed-citation id="mc-CR23" publication-type="book">Pfendner EG, Lucky AW. Junctional epidermolysis bullosa. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews. Seattle: University of Washington; 1993.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>A</given-names></name><name><surname>Chao</surname><given-names>SC</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypes</article-title><source>Hum Genet</source><year>2002</year><volume>110</volume><issue>1</issue><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00439-001-0630-1</pub-id><pub-id pub-id-type="pmid">11810295</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Nakano A, Chao SC, Pulkkinen L, et al. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypes. Hum Genet. 2002;110(1):41&#x2013;51. 10.1007/s00439-001-0630-1.<pub-id pub-id-type="pmid">11810295</pub-id>
<pub-id pub-id-type="doi">10.1007/s00439-001-0630-1</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gatalica</surname><given-names>B</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><issue>2</issue><fpage>352</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">9012408</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Gatalica B, Pulkkinen L, Li K, et al . Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. Am J Hum Genet. 1997;60(2):352&#x2013;65.<pub-id pub-id-type="pmid">9012408</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Mavilio</surname><given-names>F</given-names></name><name><surname>Pellegrini</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><issue>12</issue><fpage>1397</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/nm1504</pub-id><pub-id pub-id-type="pmid">17115047</pub-id>
</element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12(12):1397&#x2013;402. 10.1038/nm1504.<pub-id pub-id-type="pmid">17115047</pub-id>
<pub-id pub-id-type="doi">10.1038/nm1504</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>JW</given-names></name><name><surname>Koller</surname><given-names>J</given-names></name><name><surname>Murauer</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells</article-title><source>J Invest Dermatol</source><year>2017</year><volume>137</volume><issue>3</issue><fpage>778</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.10.038</pub-id><pub-id pub-id-type="pmid">27840234</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Bauer JW, Koller J, Murauer EM, et al. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol. 2017;137(3):778&#x2013;81. 10.1016/j.jid.2016.10.038.<pub-id pub-id-type="pmid">27840234</pub-id>
<pub-id pub-id-type="doi">10.1016/j.jid.2016.10.038</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>T</given-names></name><name><surname>Rothoeft</surname><given-names>T</given-names></name><name><surname>Teig</surname><given-names>N</given-names></name><etal/></person-group><article-title>Regeneration of the entire human epidermis using transgenic stem cells</article-title><source>Nature</source><year>2017</year><volume>551</volume><issue>7680</issue><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/nature24487</pub-id><pub-id pub-id-type="pmid">29144448</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327&#x2013;32. 10.1038/nature24487.<pub-id pub-id-type="pmid">29144448</pub-id>
<pub-id pub-id-type="doi">10.1038/nature24487</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Benati</surname><given-names>D</given-names></name><name><surname>Miselli</surname><given-names>F</given-names></name><name><surname>Cocchiarella</surname><given-names>F</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient</article-title><source>Mol Ther</source><year>2018</year><volume>26</volume><issue>11</issue><fpage>2592</fpage><lpage>2603</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.07.024</pub-id><pub-id pub-id-type="pmid">30122422</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Benati D, Miselli F, Cocchiarella F, et al. CRISPR/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther. 2018;26(11):2592&#x2013;603. 10.1016/j.ymthe.2018.07.024.<pub-id pub-id-type="pmid">30122422</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2018.07.024</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Takeichi</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name></person-group><article-title>Inherited ichthyosis: non-syndromic forms</article-title><source>J Dermatol</source><year>2016</year><volume>43</volume><issue>3</issue><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.13243</pub-id><pub-id pub-id-type="pmid">26945532</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Takeichi T, Akiyama M. Inherited ichthyosis: non-syndromic forms. J Dermatol. 2016;43(3):242&#x2013;51. 10.1111/1346-8138.13243.<pub-id pub-id-type="pmid">26945532</pub-id>
<pub-id pub-id-type="doi">10.1111/1346-8138.13243</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>T</given-names></name><name><surname>Choate</surname><given-names>K</given-names></name></person-group><article-title>Recent advances in understanding inherited disorders of keratinization</article-title><source>F1000Res</source><year>2018</year><pub-id pub-id-type="doi">10.12688/f1000research.14514.1</pub-id><pub-id pub-id-type="pmid">30002814</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Zaki T, Choate K. Recent advances in understanding inherited disorders of keratinization. F1000Res. 2018. 10.12688/f1000research.14514.1.<pub-id pub-id-type="pmid">30002814</pub-id>
<pub-id pub-id-type="doi">10.12688/f1000research.14514.1</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Oji</surname><given-names>V</given-names></name><name><surname>Tadini</surname><given-names>G</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Blanchet Bardon</surname><given-names>C</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Bourrat</surname><given-names>E</given-names></name><etal/></person-group><article-title>Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><issue>4</issue><fpage>607</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2009.11.020</pub-id><pub-id pub-id-type="pmid">20643494</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol. 2010;63(4):607&#x2013;41. 10.1016/j.jaad.2009.11.020.<pub-id pub-id-type="pmid">20643494</pub-id>
<pub-id pub-id-type="doi">10.1016/j.jaad.2009.11.020</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Vahlquist</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Torma</surname><given-names>H</given-names></name></person-group><article-title>Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment</article-title><source>Am J Clin Dermatol</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>51</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s40257-017-0313-x</pub-id><pub-id pub-id-type="pmid">28815464</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Vahlquist A, Fischer J, Torma H. Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):51&#x2013;66. 10.1007/s40257-017-0313-x.<pub-id pub-id-type="pmid">28815464</pub-id>
<pub-id pub-id-type="doi">10.1007/s40257-017-0313-x</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>LJ</given-names></name><name><surname>DiGiovanna</surname><given-names>JJ</given-names></name><name><surname>Rogers</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis</article-title><source>Nat Genet</source><year>1995</year><volume>9</volume><issue>3</issue><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/ng0395-279</pub-id><pub-id pub-id-type="pmid">7773290</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Russell LJ, DiGiovanna JJ, Rogers GR, et al. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat Genet. 1995;9(3):279&#x2013;83. 10.1038/ng0395-279.<pub-id pub-id-type="pmid">7773290</pub-id>
<pub-id pub-id-type="doi">10.1038/ng0395-279</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelsell</surname><given-names>DP</given-names></name><name><surname>Norgett</surname><given-names>EE</given-names></name><name><surname>Unsworth</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis</article-title><source>Am J Hum Genet</source><year>2005</year><volume>76</volume><issue>5</issue><fpage>794</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1086/429844</pub-id><pub-id pub-id-type="pmid">15756637</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Kelsell DP, Norgett EE, Unsworth H, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet. 2005;76(5):794&#x2013;803. 10.1086/429844.<pub-id pub-id-type="pmid">15756637</pub-id>
<pub-id pub-id-type="doi">10.1086/429844</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Sugiyama-Nakagiri</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><issue>7</issue><fpage>1777</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1172/JCI24834</pub-id><pub-id pub-id-type="pmid">16007253</pub-id>
</element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">Akiyama M, Sugiyama-Nakagiri Y, Sakai K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115(7):1777&#x2013;84. 10.1172/JCI24834.<pub-id pub-id-type="pmid">16007253</pub-id>
<pub-id pub-id-type="doi">10.1172/JCI24834</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><article-title>Novel compound heterozygous mutations in the CYP4F22 gene in a patient with autosomal recessive congenital ichthyosis</article-title><source>Clin Case Rep</source><year>2021</year><volume>9</volume><issue>12</issue><fpage>e05082</fpage><pub-id pub-id-type="doi">10.1002/ccr3.5082</pub-id><pub-id pub-id-type="pmid">34917360</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Tang H, Shi X, Zhang G. Novel compound heterozygous mutations in the CYP4F22 gene in a patient with autosomal recessive congenital ichthyosis. Clin Case Rep. 2021;9(12):e05082. 10.1002/ccr3.5082.<pub-id pub-id-type="pmid">34917360</pub-id>
<pub-id pub-id-type="doi">10.1002/ccr3.5082</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Esperon-Moldes</surname><given-names>U</given-names></name><name><surname>Ginarte-Val</surname><given-names>M</given-names></name><name><surname>Rodriguez-Pazos</surname><given-names>L</given-names></name><etal/></person-group><article-title>Novel CYP4F22 mutations associated with autosomal recessive congenital ichthyosis (ARCI): Study of the CYP4F22 c.1303C&gt;T founder mutation</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><issue>2</issue><fpage>e0229025</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0229025</pub-id><pub-id pub-id-type="pmid">32069299</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Esperon-Moldes U, Ginarte-Val M, Rodriguez-Pazos L, et al. Novel CYP4F22 mutations associated with autosomal recessive congenital ichthyosis (ARCI): Study of the CYP4F22 c.1303C&gt;T founder mutation. PLoS ONE. 2020;15(2): e0229025. 10.1371/journal.pone.0229025.<pub-id pub-id-type="pmid">32069299</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0229025</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Harting</surname><given-names>M</given-names></name><name><surname>Brunetti-Pierri</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Self-healing collodion membrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene</article-title><source>Arch Dermatol</source><year>2008</year><volume>144</volume><issue>3</issue><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1001/archderm.144.3.351</pub-id><pub-id pub-id-type="pmid">18347291</pub-id>
</element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Harting M, Brunetti-Pierri N, Chan CS, et al. Self-healing collodion membrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch Dermatol. 2008;144(3):351&#x2013;6. 10.1001/archderm.144.3.351.<pub-id pub-id-type="pmid">18347291</pub-id>
<pub-id pub-id-type="doi">10.1001/archderm.144.3.351</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Lesueur</surname><given-names>F</given-names></name><name><surname>Bouadjar</surname><given-names>B</given-names></name><name><surname>Lefevre</surname><given-names>C</given-names></name><etal/></person-group><article-title>Novel mutations in ALOX12B in patients with autosomal recessive congenital ichthyosis and evidence for genetic heterogeneity on chromosome 17p13</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><issue>4</issue><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700640</pub-id><pub-id pub-id-type="pmid">17139268</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Lesueur F, Bouadjar B, Lefevre C, et al. Novel mutations in ALOX12B in patients with autosomal recessive congenital ichthyosis and evidence for genetic heterogeneity on chromosome 17p13. J Invest Dermatol. 2007;127(4):829&#x2013;34. 10.1038/sj.jid.5700640.<pub-id pub-id-type="pmid">17139268</pub-id>
<pub-id pub-id-type="doi">10.1038/sj.jid.5700640</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Wajid</surname><given-names>M</given-names></name><name><surname>Kurban</surname><given-names>M</given-names></name><name><surname>Shimomura</surname><given-names>Y</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name></person-group><article-title>NIPAL4/ichthyin is expressed in the granular layer of human epidermis and mutated in two Pakistani families with autosomal recessive ichthyosis</article-title><source>Dermatology</source><year>2010</year><volume>220</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1159/000265757</pub-id><pub-id pub-id-type="pmid">20016120</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">Wajid M, Kurban M, Shimomura Y, Christiano AM. NIPAL4/ichthyin is expressed in the granular layer of human epidermis and mutated in two Pakistani families with autosomal recessive ichthyosis. Dermatology. 2010;220(1):8&#x2013;14. 10.1159/000265757.<pub-id pub-id-type="pmid">20016120</pub-id>
<pub-id pub-id-type="doi">10.1159/000265757</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation-alternatives>
          <element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Kusakabe</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>E</given-names></name><name><surname>Jitsukawa</surname><given-names>O</given-names></name><name><surname>Nishigori</surname><given-names>C</given-names></name><name><surname>Yamanishi</surname><given-names>K</given-names></name></person-group><article-title>A Japanese case of ichthyosiform erythroderma with a novel mutation in NIPAL4/Ichthyin</article-title><source>Acta Derm Venereol</source><year>2017</year><volume>97</volume><issue>3</issue><fpage>397</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.2340/00015555-2550</pub-id><pub-id pub-id-type="pmid">27868142</pub-id>
</element-citation>
          <mixed-citation id="mc-CR42" publication-type="journal">Kusakabe M, Nagai M, Nakano E, Jitsukawa O, Nishigori C, Yamanishi K. A Japanese case of ichthyosiform erythroderma with a novel mutation in NIPAL4/Ichthyin. Acta Derm Venereol. 2017;97(3):397&#x2013;8. 10.2340/00015555-2550.<pub-id pub-id-type="pmid">27868142</pub-id>
<pub-id pub-id-type="doi">10.2340/00015555-2550</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation-alternatives>
          <element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Youssefian</surname><given-names>L</given-names></name><name><surname>Vahidnezhad</surname><given-names>H</given-names></name><name><surname>Saeidian</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Autosomal recessive congenital ichthyosis: CERS3 mutations identified by a next generation sequencing panel targeting ichthyosis genes</article-title><source>Eur J Hum Genet</source><year>2017</year><volume>25</volume><issue>11</issue><fpage>1282</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2017.137</pub-id><pub-id pub-id-type="pmid">28875980</pub-id>
</element-citation>
          <mixed-citation id="mc-CR43" publication-type="journal">Youssefian L, Vahidnezhad H, Saeidian AH, et al. Autosomal recessive congenital ichthyosis: CERS3 mutations identified by a next generation sequencing panel targeting ichthyosis genes. Eur J Hum Genet. 2017;25(11):1282&#x2013;5. 10.1038/ejhg.2017.137.<pub-id pub-id-type="pmid">28875980</pub-id>
<pub-id pub-id-type="doi">10.1038/ejhg.2017.137</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation-alternatives>
          <element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Radner</surname><given-names>FP</given-names></name><name><surname>Marrakchi</surname><given-names>S</given-names></name><name><surname>Kirchmeier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mutations in CERS3 cause autosomal recessive congenital ichthyosis in humans</article-title><source>PLoS Genet</source><year>2013</year><volume>9</volume><issue>6</issue><fpage>e1003536</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1003536</pub-id><pub-id pub-id-type="pmid">23754960</pub-id>
</element-citation>
          <mixed-citation id="mc-CR44" publication-type="journal">Radner FP, Marrakchi S, Kirchmeier P, et al. Mutations in CERS3 cause autosomal recessive congenital ichthyosis in humans. PLoS Genet. 2013;9(6):e1003536. 10.1371/journal.pgen.1003536.<pub-id pub-id-type="pmid">23754960</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003536</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR45">
        <label>45</label>
        <citation-alternatives>
          <element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Hotz</surname><given-names>A</given-names></name><name><surname>Fagerberg</surname><given-names>C</given-names></name><name><surname>Vahlquist</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of mutations in SDR9C7 in six families with autosomal recessive congenital ichthyosis</article-title><source>Br J Dermatol</source><year>2018</year><volume>178</volume><issue>3</issue><fpage>e207</fpage><lpage>e209</lpage><pub-id pub-id-type="doi">10.1111/bjd.15994</pub-id><pub-id pub-id-type="pmid">28906551</pub-id>
</element-citation>
          <mixed-citation id="mc-CR45" publication-type="journal">Hotz A, Fagerberg C, Vahlquist A, et al. Identification of mutations in SDR9C7 in six families with autosomal recessive congenital ichthyosis. Br J Dermatol. 2018;178(3):e207&#x2013;9. 10.1111/bjd.15994. (<bold>PMID: 28906551</bold>).<pub-id pub-id-type="pmid">28906551</pub-id>
<pub-id pub-id-type="doi">10.1111/bjd.15994</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation-alternatives>
          <element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazereeuw-Hautier</surname><given-names>J</given-names></name><name><surname>Severino-Freire</surname><given-names>M</given-names></name><name><surname>Gaston</surname><given-names>V</given-names></name><etal/></person-group><article-title>Identification of mutations in SDR9C7 in three patients with autosomal recessive congenital ichthyosis</article-title><source>Acta Derm Venereol</source><year>2020</year><pub-id pub-id-type="doi">10.2340/00015555-3359</pub-id><pub-id pub-id-type="pmid">32157314</pub-id>
</element-citation>
          <mixed-citation id="mc-CR46" publication-type="journal">Mazereeuw-Hautier J, Severino-Freire M, Gaston V, et al. Identification of mutations in SDR9C7 in three patients with autosomal recessive congenital ichthyosis. Acta Derm Venereol. 2020. 10.2340/00015555-3359.<pub-id pub-id-type="pmid">32157314</pub-id>
<pub-id pub-id-type="doi">10.2340/00015555-3359</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation-alternatives>
          <element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Seidl-Philipp</surname><given-names>M</given-names></name><name><surname>Schossig</surname><given-names>AS</given-names></name><name><surname>Moosbrugger-Martinz</surname><given-names>V</given-names></name><name><surname>Zschocke</surname><given-names>J</given-names></name><name><surname>Schmuth</surname><given-names>M</given-names></name><name><surname>Gruber</surname><given-names>R</given-names></name></person-group><article-title>Impaired epidermal barrier in autosomal recessive congenital ichthyosis (ARCI) caused by missense mutations in SDR9C7 in two Austrian sisters</article-title><source>J Dtsch Dermatol Ges</source><year>2019</year><volume>17</volume><issue>7</issue><fpage>742</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1111/ddg.13843</pub-id><pub-id pub-id-type="pmid">31364290</pub-id>
</element-citation>
          <mixed-citation id="mc-CR47" publication-type="journal">Seidl-Philipp M, Schossig AS, Moosbrugger-Martinz V, Zschocke J, Schmuth M, Gruber R. Impaired epidermal barrier in autosomal recessive congenital ichthyosis (ARCI) caused by missense mutations in SDR9C7 in two Austrian sisters. J Dtsch Dermatol Ges. 2019;17(7):742&#x2013;5. 10.1111/ddg.13843.<pub-id pub-id-type="pmid">31364290</pub-id>
<pub-id pub-id-type="doi">10.1111/ddg.13843</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation-alternatives>
          <element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Shigehara</surname><given-names>Y</given-names></name><name><surname>Okuda</surname><given-names>S</given-names></name><name><surname>Nemer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Mutations in SDR9C7 gene encoding an enzyme for vitamin A metabolism underlie autosomal recessive congenital ichthyosis</article-title><source>Hum Mol Genet</source><year>2016</year><volume>25</volume><issue>20</issue><fpage>4484</fpage><lpage>4493</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw277</pub-id><pub-id pub-id-type="pmid">28173123</pub-id>
</element-citation>
          <mixed-citation id="mc-CR48" publication-type="journal">Shigehara Y, Okuda S, Nemer G, et al. Mutations in SDR9C7 gene encoding an enzyme for vitamin A metabolism underlie autosomal recessive congenital ichthyosis. Hum Mol Genet. 2016;25(20):4484&#x2013;93. 10.1093/hmg/ddw277.<pub-id pub-id-type="pmid">28173123</pub-id>
<pub-id pub-id-type="doi">10.1093/hmg/ddw277</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation-alternatives>
          <element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>HJ</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>PC</given-names></name><etal/></person-group><article-title>A Chinese family with autosomal recessive congenital ichthyosis and Leber congenital amaurosis due to mutations in PNPLA1 and LCA5</article-title><source>Eur J Dermatol</source><year>2018</year><pub-id pub-id-type="doi">10.1684/ejd.2018.3221</pub-id><pub-id pub-id-type="pmid">29941414</pub-id>
</element-citation>
          <mixed-citation id="mc-CR49" publication-type="journal">Zhao HJ, Zeng X, Lei PC, et al. A Chinese family with autosomal recessive congenital ichthyosis and Leber congenital amaurosis due to mutations in PNPLA1 and LCA5. Eur J Dermatol. 2018. 10.1684/ejd.2018.3221.<pub-id pub-id-type="pmid">29941414</pub-id>
<pub-id pub-id-type="doi">10.1684/ejd.2018.3221</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation-alternatives>
          <element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Vahidnezhad</surname><given-names>H</given-names></name><name><surname>Youssefian</surname><given-names>L</given-names></name><name><surname>Saeidian</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Gene-targeted next generation sequencing identifies PNPLA1 mutations in patients with a phenotypic spectrum of autosomal recessive congenital ichthyosis: the impact of consanguinity</article-title><source>J Invest Dermatol</source><year>2017</year><volume>137</volume><issue>3</issue><fpage>678</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.11.012</pub-id><pub-id pub-id-type="pmid">27884779</pub-id>
</element-citation>
          <mixed-citation id="mc-CR50" publication-type="journal">Vahidnezhad H, Youssefian L, Saeidian AH, et al. Gene-targeted next generation sequencing identifies PNPLA1 mutations in patients with a phenotypic spectrum of autosomal recessive congenital ichthyosis: the impact of consanguinity. J Invest Dermatol. 2017;137(3):678&#x2013;85. 10.1016/j.jid.2016.11.012.<pub-id pub-id-type="pmid">27884779</pub-id>
<pub-id pub-id-type="doi">10.1016/j.jid.2016.11.012</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation-alternatives>
          <element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Dokmeci-Emre</surname><given-names>S</given-names></name><name><surname>Taskiran</surname><given-names>ZE</given-names></name><name><surname>Yuzbasioglu</surname><given-names>A</given-names></name></person-group><article-title>Identification of two novel PNPLA1 mutations in Turkish families with autosomal recessive congenital ichthyosis</article-title><source>Turk J Pediatr</source><year>2017</year><volume>59</volume><issue>4</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.24953/turkjped.2017.04.017</pub-id><pub-id pub-id-type="pmid">29624231</pub-id>
</element-citation>
          <mixed-citation id="mc-CR51" publication-type="journal">Dokmeci-Emre S, Taskiran ZE, Yuzbasioglu A, et al. Identification of two novel PNPLA1 mutations in Turkish families with autosomal recessive congenital ichthyosis. Turk J Pediatr. 2017;59(4):475&#x2013;82. 10.24953/turkjped.2017.04.017.<pub-id pub-id-type="pmid">29624231</pub-id>
<pub-id pub-id-type="doi">10.24953/turkjped.2017.04.017</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation-alternatives>
          <element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Esperon-Moldes</surname><given-names>U</given-names></name><name><surname>Ginarte Val</surname><given-names>M</given-names></name><name><surname>Rodriguez-Pazos</surname><given-names>L</given-names></name><etal/></person-group><article-title>Novel and recurrent PNPLA1 mutations in Spanish patients with autosomal recessive congenital ichthyosis; evidence of a founder effect</article-title><source>Acta Derm Venereol</source><year>2019</year><volume>99</volume><issue>10</issue><fpage>894</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.2340/00015555-3227</pub-id><pub-id pub-id-type="pmid">31120544</pub-id>
</element-citation>
          <mixed-citation id="mc-CR52" publication-type="journal">Esperon-Moldes U, Ginarte Val M, Rodriguez-Pazos L, et al. Novel and recurrent PNPLA1 mutations in Spanish patients with autosomal recessive congenital ichthyosis; evidence of a founder effect. Acta Derm Venereol. 2019;99(10):894&#x2013;8. 10.2340/00015555-3227.<pub-id pub-id-type="pmid">31120544</pub-id>
<pub-id pub-id-type="doi">10.2340/00015555-3227</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR53">
        <label>53</label>
        <citation-alternatives>
          <element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Diociaiuti</surname><given-names>A</given-names></name><name><surname>Pisaneschi</surname><given-names>E</given-names></name><name><surname>Zambruno</surname><given-names>G</given-names></name><etal/></person-group><article-title>Novel PNPLA1 mutations in two Italian siblings with autosomal recessive congenital ichthyosis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2018</year><volume>32</volume><issue>3</issue><fpage>e110</fpage><lpage>e112</lpage><pub-id pub-id-type="doi">10.1111/jdv.14618</pub-id><pub-id pub-id-type="pmid">28983987</pub-id>
</element-citation>
          <mixed-citation id="mc-CR53" publication-type="journal">Diociaiuti A, Pisaneschi E, Zambruno G, et al. Novel PNPLA1 mutations in two Italian siblings with autosomal recessive congenital ichthyosis. J Eur Acad Dermatol Venereol. 2018;32(3):e110&#x2013;2. 10.1111/jdv.14618.<pub-id pub-id-type="pmid">28983987</pub-id>
<pub-id pub-id-type="doi">10.1111/jdv.14618</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation-alternatives>
          <element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Grall</surname><given-names>A</given-names></name><name><surname>Guaguere</surname><given-names>E</given-names></name><name><surname>Planchais</surname><given-names>S</given-names></name><etal/></person-group><article-title>PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><issue>2</issue><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/ng.1056</pub-id><pub-id pub-id-type="pmid">22246504</pub-id>
</element-citation>
          <mixed-citation id="mc-CR54" publication-type="journal">Grall A, Guaguere E, Planchais S, et al. PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nat Genet. 2012;44(2):140&#x2013;7. 10.1038/ng.1056.<pub-id pub-id-type="pmid">22246504</pub-id>
<pub-id pub-id-type="doi">10.1038/ng.1056</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation-alternatives>
          <element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>AD</given-names></name><name><surname>Kim</surname><given-names>GJ</given-names></name><name><surname>Hotz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function</article-title><source>Br J Dermatol</source><year>2017</year><volume>177</volume><issue>2</issue><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1111/bjd.15308</pub-id><pub-id pub-id-type="pmid">28093717</pub-id>
</element-citation>
          <mixed-citation id="mc-CR55" publication-type="journal">Zimmer AD, Kim GJ, Hotz A, et al. Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function. Br J Dermatol. 2017;177(2):445&#x2013;55. 10.1111/bjd.15308.<pub-id pub-id-type="pmid">28093717</pub-id>
<pub-id pub-id-type="doi">10.1111/bjd.15308</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation-alternatives>
          <element-citation id="ec-CR56" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Targeted regions sequencing identified four novel PNPLA1 mutations in two Chinese families with autosomal recessive congenital ichthyosis</article-title>
            <source>Mol Genet Genom Med</source>
            <year>2020</year>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>e1076</fpage>
            <pub-id pub-id-type="doi">10.1002/mgg3.1076</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR56" publication-type="journal">Li L, Liu W, Xu Y, et al. Targeted regions sequencing identified four novel PNPLA1 mutations in two Chinese families with autosomal recessive congenital ichthyosis. Mol Genet Genom Med. 2020;8(2): e1076. 10.1002/mgg3.1076.<pub-id pub-id-type="doi">10.1002/mgg3.1076</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation-alternatives>
          <element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Sobol</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>N</given-names></name><name><surname>Klar</surname><given-names>J</given-names></name></person-group><article-title>FATP4 missense and nonsense mutations cause similar features in ichthyosis prematurity syndrome</article-title><source>BMC Res Notes</source><year>2011</year><volume>4</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/1756-0500-4-90</pub-id><pub-id pub-id-type="pmid">21450060</pub-id>
</element-citation>
          <mixed-citation id="mc-CR57" publication-type="journal">Sobol M, Dahl N, Klar J. FATP4 missense and nonsense mutations cause similar features in ichthyosis prematurity syndrome. BMC Res Notes. 2011;4:90. 10.1186/1756-0500-4-90.<pub-id pub-id-type="pmid">21450060</pub-id>
<pub-id pub-id-type="doi">10.1186/1756-0500-4-90</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation-alternatives>
          <element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Inhoff</surname><given-names>O</given-names></name><name><surname>Hausser</surname><given-names>I</given-names></name><name><surname>Schneider</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Ichthyosis prematurity syndrome caused by a novel fatty acid transport protein 4 gene mutation in a German infant</article-title><source>Arch Dermatol</source><year>2011</year><volume>147</volume><issue>6</issue><fpage>750</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2011.139</pub-id><pub-id pub-id-type="pmid">21690550</pub-id>
</element-citation>
          <mixed-citation id="mc-CR58" publication-type="journal">Inhoff O, Hausser I, Schneider SW, et al. Ichthyosis prematurity syndrome caused by a novel fatty acid transport protein 4 gene mutation in a German infant. Arch Dermatol. 2011;147(6):750&#x2013;2. 10.1001/archdermatol.2011.139.<pub-id pub-id-type="pmid">21690550</pub-id>
<pub-id pub-id-type="doi">10.1001/archdermatol.2011.139</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation-alternatives>
          <element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>R</given-names></name><name><surname>Santhanam</surname><given-names>S</given-names></name><name><surname>Samuel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ichthyosis prematurity syndrome caused by a novel missense mutation in FATP4 gene-a case report from India</article-title><source>Clin Case Rep</source><year>2016</year><volume>4</volume><issue>1</issue><fpage>87</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/ccr3.462</pub-id><pub-id pub-id-type="pmid">26783444</pub-id>
</element-citation>
          <mixed-citation id="mc-CR59" publication-type="journal">George R, Santhanam S, Samuel R, et al. Ichthyosis prematurity syndrome caused by a novel missense mutation in FATP4 gene-a case report from India. Clin Case Rep. 2016;4(1):87&#x2013;9. 10.1002/ccr3.462.<pub-id pub-id-type="pmid">26783444</pub-id>
<pub-id pub-id-type="doi">10.1002/ccr3.462</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation-alternatives>
          <element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Diociaiuti</surname><given-names>A</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Paglietti</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Ichthyosis prematurity syndrome due to a novel SLC27A4 homozygous mutation in an Italian patient</article-title><source>Acta Derm Venereol</source><year>2018</year><volume>98</volume><issue>8</issue><fpage>803</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.2340/00015555-2957</pub-id><pub-id pub-id-type="pmid">29701233</pub-id>
</element-citation>
          <mixed-citation id="mc-CR60" publication-type="journal">Diociaiuti A, Rosati E, Paglietti MG, et al. Ichthyosis prematurity syndrome due to a novel SLC27A4 homozygous mutation in an Italian patient. Acta Derm Venereol. 2018;98(8):803&#x2013;4. 10.2340/00015555-2957.<pub-id pub-id-type="pmid">29701233</pub-id>
<pub-id pub-id-type="doi">10.2340/00015555-2957</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR61">
        <label>61</label>
        <citation-alternatives>
          <element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Al Mandhari</surname><given-names>H</given-names></name><name><surname>Al-Musalhi</surname><given-names>B</given-names></name><name><surname>Al Mahroqi</surname><given-names>N</given-names></name><name><surname>Hilmarsen</surname><given-names>HT</given-names></name><name><surname>Braathen</surname><given-names>GJ</given-names></name><name><surname>Khnykin</surname><given-names>D</given-names></name></person-group><article-title>Ichthyosis prematurity syndrome in two Omani siblings, caused by homozygous c.1A &gt; G mutation in the FATP4 gene</article-title><source>Int J Dermatol</source><year>2021</year><volume>60</volume><issue>3</issue><fpage>368</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1111/ijd.15367</pub-id><pub-id pub-id-type="pmid">33319372</pub-id>
</element-citation>
          <mixed-citation id="mc-CR61" publication-type="journal">Al Mandhari H, Al-Musalhi B, Al Mahroqi N, Hilmarsen HT, Braathen GJ, Khnykin D. Ichthyosis prematurity syndrome in two Omani siblings, caused by homozygous c.1A &gt; G mutation in the FATP4 gene. Int J Dermatol. 2021;60(3):368&#x2013;71. 10.1111/ijd.15367.<pub-id pub-id-type="pmid">33319372</pub-id>
<pub-id pub-id-type="doi">10.1111/ijd.15367</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR62">
        <label>62</label>
        <citation-alternatives>
          <element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Kiely</surname><given-names>C</given-names></name><name><surname>Devaney</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Lenane</surname><given-names>P</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name></person-group><article-title>Ichthyosis prematurity syndrome: a case report and review of known mutations</article-title><source>Pediatr Dermatol</source><year>2014</year><volume>31</volume><issue>4</issue><fpage>517</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1111/pde.12320</pub-id><pub-id pub-id-type="pmid">24889544</pub-id>
</element-citation>
          <mixed-citation id="mc-CR62" publication-type="journal">Kiely C, Devaney D, Fischer J, Lenane P, Irvine AD. Ichthyosis prematurity syndrome: a case report and review of known mutations. Pediatr Dermatol. 2014;31(4):517&#x2013;8. 10.1111/pde.12320.<pub-id pub-id-type="pmid">24889544</pub-id>
<pub-id pub-id-type="doi">10.1111/pde.12320</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation-alternatives>
          <element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuge</surname><given-names>I</given-names></name><name><surname>Morishita</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of novel FATP4 mutations in a Japanese patient with ichthyosis prematurity syndrome</article-title><source>Hum Genome Var</source><year>2015</year><volume>2</volume><fpage>15003</fpage><pub-id pub-id-type="doi">10.1038/hgv.2015.3</pub-id><pub-id pub-id-type="pmid">27081519</pub-id>
</element-citation>
          <mixed-citation id="mc-CR63" publication-type="journal">Tsuge I, Morishita M, Kato T, et al. Identification of novel FATP4 mutations in a Japanese patient with ichthyosis prematurity syndrome. Hum Genome Var. 2015;2:15003. 10.1038/hgv.2015.3.<pub-id pub-id-type="pmid">27081519</pub-id>
<pub-id pub-id-type="doi">10.1038/hgv.2015.3</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation-alternatives>
          <element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Klar</surname><given-names>J</given-names></name><name><surname>Schweiger</surname><given-names>M</given-names></name><name><surname>Zimmerman</surname><given-names>R</given-names></name><name><surname>Zechner</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Torma</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome</article-title><source>Am J Hum Genet</source><year>2009</year><volume>85</volume><issue>2</issue><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.06.021</pub-id><pub-id pub-id-type="pmid">19631310</pub-id>
</element-citation>
          <mixed-citation id="mc-CR64" publication-type="journal">Klar J, Schweiger M, Zimmerman R, et al. Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome. Am J Hum Genet. 2009;85(2):248&#x2013;53. 10.1016/j.ajhg.2009.06.021.<pub-id pub-id-type="pmid">19631310</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2009.06.021</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation-alternatives>
          <element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Esperon-Moldes</surname><given-names>US</given-names></name><name><surname>Ginarte</surname><given-names>M</given-names></name><name><surname>Santamarina</surname><given-names>M</given-names></name><name><surname>Rodriguez-Lage</surname><given-names>B</given-names></name><name><surname>Rodriguez-Pazos</surname><given-names>L</given-names></name><name><surname>Vega</surname><given-names>A</given-names></name></person-group><article-title>Novel compound heterozygous FATP4 mutations caused ichthyosis prematurity syndrome in Spanish sisters</article-title><source>Acta Paediatr</source><year>2019</year><volume>108</volume><issue>4</issue><fpage>763</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1111/apa.14694</pub-id><pub-id pub-id-type="pmid">30536735</pub-id>
</element-citation>
          <mixed-citation id="mc-CR65" publication-type="journal">Esperon-Moldes US, Ginarte M, Santamarina M, Rodriguez-Lage B, Rodriguez-Pazos L, Vega A. Novel compound heterozygous FATP4 mutations caused ichthyosis prematurity syndrome in Spanish sisters. Acta Paediatr. 2019;108(4):763&#x2013;5. 10.1111/apa.14694.<pub-id pub-id-type="pmid">30536735</pub-id>
<pub-id pub-id-type="doi">10.1111/apa.14694</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation-alternatives>
          <element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>E</given-names></name><name><surname>Canueto</surname><given-names>J</given-names></name><name><surname>Garcia-Patos</surname><given-names>V</given-names></name></person-group><article-title>Novel mutations in FATP4 gene in two families with ichthyosis prematurity syndrome</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><issue>1</issue><fpage>e11</fpage><lpage>e13</lpage><pub-id pub-id-type="doi">10.1111/jdv.13584</pub-id><pub-id pub-id-type="pmid">27168232</pub-id>
</element-citation>
          <mixed-citation id="mc-CR66" publication-type="journal">Bueno E, Canueto J, Garcia-Patos V, , et al. Novel mutations in FATP4 gene in two families with ichthyosis prematurity syndrome. J Eur Acad Dermatol Venereol. 2017;31(1):e11&#x2013;3. 10.1111/jdv.13584.<pub-id pub-id-type="pmid">27168232</pub-id>
<pub-id pub-id-type="doi">10.1111/jdv.13584</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation-alternatives>
          <element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Israeli</surname><given-names>S</given-names></name><name><surname>Khamaysi</surname><given-names>Z</given-names></name><name><surname>Fuchs-Telem</surname><given-names>D</given-names></name><etal/></person-group><article-title>A mutation in LIPN, encoding epidermal lipase N, causes a late-onset form of autosomal-recessive congenital ichthyosis</article-title><source>Am J Hum Genet</source><year>2011</year><volume>88</volume><issue>4</issue><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.02.011</pub-id><pub-id pub-id-type="pmid">21439540</pub-id>
</element-citation>
          <mixed-citation id="mc-CR67" publication-type="journal">Israeli S, Khamaysi Z, Fuchs-Telem D, et al. A mutation in LIPN, encoding epidermal lipase N, causes a late-onset form of autosomal-recessive congenital ichthyosis. Am J Hum Genet. 2011;88(4):482&#x2013;7. 10.1016/j.ajhg.2011.02.011.<pub-id pub-id-type="pmid">21439540</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.02.011</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation-alternatives>
          <element-citation id="ec-CR68" publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Richard</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Autosomal recessive congenital ichthyosis</article-title>
            <source>GeneReviews</source>
            <year>1993</year>
            <publisher-loc>Seattle</publisher-loc>
            <publisher-name>University of Washington</publisher-name>
          </element-citation>
          <mixed-citation id="mc-CR68" publication-type="book">Richard G, et al. Autosomal recessive congenital ichthyosis. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews. Seattle: University of Washington; 1993.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation-alternatives>
          <element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Choate</surname><given-names>KA</given-names></name><name><surname>Kinsella</surname><given-names>TM</given-names></name><name><surname>Williams</surname><given-names>ML</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Khavari</surname><given-names>PA</given-names></name></person-group><article-title>Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes</article-title><source>Hum Gene Ther</source><year>1996</year><volume>7</volume><issue>18</issue><fpage>2247</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1089/hum.1996.7.18-2247</pub-id><pub-id pub-id-type="pmid">8953315</pub-id>
</element-citation>
          <mixed-citation id="mc-CR69" publication-type="journal">Choate KA, Kinsella TM, Williams ML, Nolan GP, Khavari PA. Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes. Hum Gene Ther. 1996;7(18):2247&#x2013;53. 10.1089/hum.1996.7.18-2247.<pub-id pub-id-type="pmid">8953315</pub-id>
<pub-id pub-id-type="doi">10.1089/hum.1996.7.18-2247</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation-alternatives>
          <element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>JC</given-names></name><name><surname>Parry</surname><given-names>TJ</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Preclinical evaluation of a modified herpes simplex virus type 1 vector encoding human TGM1 for the treatment of autosomal recessive congenital ichthyosis</article-title><source>J Invest Dermatol</source><year>2021</year><volume>141</volume><issue>4</issue><fpage>874</fpage><lpage>82.e6</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2020.07.035</pub-id><pub-id pub-id-type="pmid">32976879</pub-id>
</element-citation>
          <mixed-citation id="mc-CR70" publication-type="journal">Freedman JC, Parry TJ, Zhang P, et al. Preclinical evaluation of a modified herpes simplex virus type 1 vector encoding human TGM1 for the treatment of autosomal recessive congenital ichthyosis. J Invest Dermatol. 2021;141(4):874-82.e6. 10.1016/j.jid.2020.07.035.<pub-id pub-id-type="pmid">32976879</pub-id>
<pub-id pub-id-type="doi">10.1016/j.jid.2020.07.035</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation-alternatives>
          <element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Correction of the pathogenic mutation in TGM1 gene by adenine base editing in mutant embryos</article-title><source>Mol Ther</source><year>2022</year><volume>30</volume><issue>1</issue><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.05.007</pub-id><pub-id pub-id-type="pmid">33974999</pub-id>
</element-citation>
          <mixed-citation id="mc-CR71" publication-type="journal">Dang L, Zhou X, Zhong X, et al. Correction of the pathogenic mutation in TGM1 gene by adenine base editing in mutant embryos. Mol Ther. 2022;30(1):175&#x2013;83. 10.1016/j.ymthe.2021.05.007.<pub-id pub-id-type="pmid">33974999</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2021.05.007</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation-alternatives>
          <element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>ML</given-names></name><name><surname>Elias</surname><given-names>PM</given-names></name></person-group><article-title>Genetically transmitted, generalized disorders of cornification: the ichthyoses</article-title><source>Dermatol Clin</source><year>1987</year><volume>5</volume><issue>1</issue><fpage>155</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/S0733-8635(18)30772-1</pub-id><pub-id pub-id-type="pmid">3549075</pub-id>
</element-citation>
          <mixed-citation id="mc-CR72" publication-type="journal">Williams ML, Elias PM. Genetically transmitted, generalized disorders of cornification: the ichthyoses. Dermatol Clin. 1987;5(1):155&#x2013;78.<pub-id pub-id-type="pmid">3549075</pub-id>
<pub-id pub-id-type="doi">10.1016/S0733-8635(18)30772-1</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation-alternatives>
          <element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>BA</given-names></name><name><surname>Holbrook</surname><given-names>KA</given-names></name><name><surname>Fleckman</surname><given-names>P</given-names></name><name><surname>Kimball</surname><given-names>JR</given-names></name><name><surname>Brumbaugh</surname><given-names>S</given-names></name><name><surname>Sybert</surname><given-names>VP</given-names></name></person-group><article-title>Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules</article-title><source>J Invest Dermatol</source><year>1990</year><volume>94</volume><issue>1</issue><fpage>6</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12873301</pub-id><pub-id pub-id-type="pmid">1688598</pub-id>
</element-citation>
          <mixed-citation id="mc-CR73" publication-type="journal">Dale BA, Holbrook KA, Fleckman P, Kimball JR, Brumbaugh S, Sybert VP. Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol. 1990;94(1):6&#x2013;18. 10.1111/1523-1747.ep12873301.<pub-id pub-id-type="pmid">1688598</pub-id>
<pub-id pub-id-type="doi">10.1111/1523-1747.ep12873301</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation-alternatives>
          <element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Main</surname><given-names>DM</given-names></name><name><surname>Otto</surname><given-names>CE</given-names></name><name><surname>Holbrook</surname><given-names>KA</given-names></name></person-group><article-title>Characteristic morphologic abnormality of harlequin ichthyosis detected in amniotic fluid cells</article-title><source>J Invest Dermatol</source><year>1994</year><volume>102</volume><issue>2</issue><fpage>210</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12371764</pub-id><pub-id pub-id-type="pmid">8106750</pub-id>
</element-citation>
          <mixed-citation id="mc-CR74" publication-type="journal">Akiyama M, Kim DK, Main DM, Otto CE, Holbrook KA. Characteristic morphologic abnormality of harlequin ichthyosis detected in amniotic fluid cells. J Invest Dermatol. 1994;102(2):210&#x2013;3. 10.1111/1523-1747.ep12371764.<pub-id pub-id-type="pmid">8106750</pub-id>
<pub-id pub-id-type="doi">10.1111/1523-1747.ep12371764</pub-id></mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>